Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease

Stopped A study start is currently not foreseeable for organizational reasons. Due to the delays, research has also been focused on new compounds, which has reduced the interest in the potential results of the above-mentioned clinical trial.

Conditions

• Type 2 Diabetes
• Cardiovascular Diseases

Interventions

• DRUG: Liraglutide Pen Injector [Victoza]
• DRUG: Placebo

Sponsor

RWTH Aachen University

Collaborators

• [object Object]